YO-2
YO-2 is a plasmin inhibitor and TP53 upregulator with anti-tumor and apoptosis-inducing activities. YO-2 upregulates the expression of TP53 and the tumor-suppressive miR-103/107, downregulates LRP1, and induces cellular DNA fragmentation and caspase cascade activation. YO-2 effectively blocks the growth of melanoma. YO-2 has been widely used in studies related to melanoma and colon cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 288254-44-4
- 分子式: C31H46N4O3
- 分子量:522.72
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
体外実験
YO-2 (10-30 μM; 24 h) dose-dependently inhibits plasminogen-induced proliferation of murine B16F10 melanoma cells after 24 h of incubation[1].
YO-2 (10-30 μM; 24 h) dose-dependently activates caspase 3/7 in murine B16F10 melanoma cells, with a ~10-fold increase in activity at 30 μM after 24 h of incubation[1].
YO-2 (10-30 μM; 24 h) dose-dependently downregulates anti-apoptotic BCL2 gene expression in murine B16F10 melanoma cells after 24 h of incubation[1].
YO-2 (10-20 μM) increases p53 protein levels in murine B16F10 melanoma cells at concentrations of 10 μM and 20 μM[1].
YO-2 (10-30 μM) dose-dependently upregulates p53 protein levels in murine B16F10 melanoma cells at concentrations of 10 μM, 20 μM, and 30 μM[1].
YO-2 (30 μM; 1-6 h) induces apoptotic morphological changes in rat thymocytes, including time-dependent phosphatidylserine translocation and chromatin condensation, when treated with 30 μM YO-2 for 1 to 6 h[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:murine B16F10 melanoma cells
-
Concentration:10-30 μM
-
Incubation Time:24 h
-
Result:Increased caspase 3/7 activity in a dose-dependent fashion.
Induced a ~3-fold increase at 10 μM compared to PBS-treated controls.
Induced a ~6-fold increase at 20 μM compared to PBS-treated controls.
Induced a ~10-fold increase at 30 μM compared to PBS-treated controls.
体内実験
Cotreatment with YO-2 (5 mg/kg; i.p.; every other day; starting day 5 post-tumor inoculation) and a single 1 mg/kg dose of Doxorubicin (HY-15142A) (day 0 post-tumor inoculation) significantly reduces melanoma tumor weight more effectively than either agent alone in a murine subcutaneous melanoma model[1].
YO-2 (5 mg/kg; i.p.; daily; starting day 5 post-tumor inoculation) significantly reduces tumor weight in mice bearing LRP1-overexpressing subcutaneous melanoma tumors[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (8- to 12-week-old male; wild-type; subcutaneous inoculation of 1×106 B16F10 melanoma cells)[1]
-
Dosage:5 mg/kg
-
Administration:i.p.; daily; starting day 5 post-tumor inoculation
-
Result:Reduced mean tumor weight from ~3.2 g (control) to ~1.0 g.
Increased expression of TP53, p21, miR-103, and miR-107 in tumor tissues.
Decreased expression of LRP1 in tumor tissues.
-
Animal Model:C57BL/6 (8- to 12-week-old male; wild-type; subcutaneous inoculation of 1×106 B16F10 melanoma cells)[1]
-
Dosage:5 mg/kg (YO-2); 1 mg/kg (doxorubicin)
-
Administration:i.p. (YO-2; every other day; starting day 5 post-tumor inoculation); single dose (doxorubicin; day 0 post-tumor inoculation)
-
Result:Reduced mean tumor weight to ~0.7 g, compared to ~2.8 g (untreated control), ~1.5 g (YO-2 alone), and ~2.5 g (doxorubicin alone).
-
Animal Model:C57BL/6 (8- to 12-week-old male; wild-type; subcutaneous inoculation of 1×106 LRP1-overexpressing B16F10 melanoma cells)[1]
-
Dosage:5 mg/kg
-
Administration:i.p.; daily; starting day 5 post-tumor inoculation
-
Result:Reduced mean tumor weight from ~4.0 g (untreated control) to ~2.0 g in LRP1-overexpressing tumors.
化学情報
-
CAS 番号 288254-44-4
-
分子量 522.72
-
分子式 C31H46N4O3
-
SMILES
O=C([C@H]1CC[C@@H](CC1)CN)N[C@H](C(NCCCCCCCC)=O)CC2=CC=C(C=C2)OCC3=CC=NC=C3
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
純度とドキュメンテーション
参考文献
[1]. Salama Y, et al. YO2 Induces Melanoma Cell Apoptosis through p53-Mediated LRP1 Downregulation. Cancers (Basel). 2022;15(1):288. Published 2022 Dec 31. [Content Brief]
[2]. Lee E, et al. A selective plasmin inhibitor, trans-aminomethylcyclohexanecarbonyl-L-(O-picolyl)tyrosine-octylamide (YO-2), induces thymocyte apoptosis. Biochem Pharmacol. 2002;63(7):1315-1323. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)